Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

So, while you should always follow the fundamentals of healthy living – like exercising and eating a balanced diet – ...

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

led by FreeStyle Libre. The nutritional segment is benefiting from market share gains for its baby formula products. Abbott expects its total 2024 revenue to rise 9.5% to 10% on an organic basis.

Designed to track glucose in real time, Lingo is based on Abbott's FreeStyle Libre CGM technology ... It is also accessible in the UK. Per a Grand View Research report, the global CGM devices ...

Abbott’s FreeStyle Libre devices involve a small sensor applied ... Abbott’s industry partners seem to view these collaborations in the same way. Que Dallara, president of Medtronic Diabetes ...

Jim Cramer notes that with the market currently overbought—reflected in the S&P short-range oscillator reading of plus five—Larry’s view ... Abbott Laboratories (NYSE:ABT)’s FreeStyle ...

DexCom’s action seemingly intended to capitalize on that view. But by initiating a lawsuit at the UPC, DexCom risked Abbott filing a (ultimately successful) counterclaim for revocation.